scispace - formally typeset
Open AccessJournal ArticleDOI

Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

TLDR
The results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive, with large demonstration projects needed to fully evaluate this strategy.
Abstract
Several studies suggest that HPV testing is more sensitive than cytology in primary cervical screening. These studies had different designs and were reported in different ways. Individual patient data were collected for all European and North American studies in which cytology was routinely performed and HPV testing was included as an additional parallel test. More than 60,000 women were included. The sensitivity and specificity of HPV testing were compared with routine cytology, both overall and for ages <35, 35–49 and 50+. The age-specific prevalence of high risk HPV (hr-HPV) was also analysed. HPV testing was substantially more sensitive in detecting CIN2+ than cytology (96.1% vs. 53.0%) but less specific (90.7% vs. 96.3%). The sensitivity of HPV testing was similar in all studies carried out in different areas of Europe and North America, whereas the sensitivity of cytology was highly variable. HPV sensitivity was uniformly high at all ages, whereas the sensitivity of cytology was substantially better in women over the age of 50 than in younger women (79.3% vs. 59.6%). The specificity of both tests increased with age. Positivity rates for HPV testing in women without high-grade CIN were region dependent. These results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive. Large demonstration projects are needed to fully evaluate this strategy. © 2006 Wiley-Liss, Inc.

read more

Citations
More filters
Journal ArticleDOI

Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens.

TL;DR: Improved performance of the BD assay with respect to ability to provide extended genotyping information and lack of cross-reactivity with low-risk HPV types associated with cellular abnormalities was revealed and the relative risks for CIN 3 disease for HPV 31 and HPV 33/58 were comparable to that of HPV 18 in this population.
Journal ArticleDOI

DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort

TL;DR: Methylation results from both independent cohorts were comparable as well as high sensitivity for detection of cervical cancer and its high‐grade precursors in hrHPV‐positive population.
Journal ArticleDOI

Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer.

TL;DR: An enhanced version of this prototypic p16INK4a ELISA showed promise in screening, particularly when combined with hc2, and was referred for histologic diagnosis.
Journal ArticleDOI

Risk Factors for Squamous Intraepithelial Lesions in Systemic Lupus Erythematosus: A Prospective Cohort Study

TL;DR: A prospective cohort study was undertaken to ascertain the risk factors for the development of squamous intraepithelial lesions (SIL) in patients with systemic lupus erythematosus (SLE).
Journal ArticleDOI

Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test.

TL;DR: The novel PapilloCheck® genotyping test was compared with SPF10 PCR LiPav1 and PGMY09/11 on hybrid capture 2 (HC2)‐pretested samples and results show a necessity for the standardization of genotype‐specific HPV detection assays.
References
More filters
Journal ArticleDOI

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Journal ArticleDOI

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study

TL;DR: The findings suggest that attempts to exploit the association between cervical neoplasia and HPV infection to improve effectiveness of cervical screening programmes might be undermined by the limited inferences that can be drawn from the characterisation of a woman's HPV status at a single point in time, and the short lead time gained by its detection.
Journal ArticleDOI

Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

TL;DR: Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of cervical intraepithelial neoplasia CIN 3, and all women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dysKaryosis ought to be referred only after a second positive test for high- risk human papillsomav virus at 6 months.
Journal ArticleDOI

Trends in mortality from cervical cancer in the nordic countries: association with organised screening programmes

TL;DR: Investigation of time trends in mortality from cervical cancer in Denmark, Finland, Iceland, Norway, and Sweden since the early 1950s supports the conclusion that organised screening programmes have had a major impact on the reduction in mortality in the Nordic countries.
Journal ArticleDOI

Management of women who test positive for high-risk types of human papillomavirus: The HART study

TL;DR: Comparison of the detection rate and positive predictive values of HPV assay with cytology and the best management strategy for HPV-positive women found HPV testing was more sensitive than borderline or worse cytology but less specific for detecting CIN2+.
Related Papers (5)